SAGE241115C22500
- 0.05
- 0.000.00%
Sage Therapeutics Newsroom
Earnings Preview: SAGE to Report Financial Results Post-market on October 29
$Sage Therapeutics(SAGE.US)$ is scheduled to release its financial results post-market on October 29 ET. Earnings PreviewAnalysts estimate $Sage Therapeutics(SAGE.US)$ to post revenue of USD11.12M
TD Cowen Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $10
State Street Corp's Strategic Acquisition of Sage Therapeutics Shares
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $17
Scotiabank Reaffirms Their Buy Rating on SAGE Therapeutics (SAGE)
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Sage Therapeutics undergoes a global strategy restructuring and will lay off 165 people.
On October 17th, Glonhui reported that USA biopharmaceutical company sage therapeutics announced a global strategy restructuring, with the company laying off 165 people, accounting for about 33% of the total number of employees. In addition, the company will prioritize the commercialization of the depression drug Zurzuvae produced jointly with Bozhi, and focus on its development portfolio.
SAGE Therapeutics' Strategic Reorganization and Cautious Hold Rating Amid Development Setbacks
Needham Reiterates Hold on Sage Therapeutics
Express News | Sage Therapeutics Inc : Wedbush Cuts Target Price to $7 From $8
Sage Therapeutics Cutting Workforce by 33%
Express News | Sage Therapeutics: Approved Separation of Kimi Iguchi, CFO, and Anne Marie Cook, Senior Vp, General Counsel, and Secretary
Express News | Sage Therapeutics Inc - Chris Benecchi to Become Chief Operating Officer
Express News | Sage Therapeutics Inc - Expects Non-Recurring Charge of $26M-$28M
Express News | Sage Therapeutics Inc - to Reduce Workforce by Approximately 33%
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE Commercialization and Focus Its Development Portfolio
Express News | Sage Therapeutics Announces Strategic Reorganization to Prioritize Zurzuvae® Commercialization and Focus Its Development Portfolio
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Raymond James Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Raymond James Reinstates Market Perform on Sage Therapeutics